Table 1.
Baseline characteristics
| HC (N = 20) | Pso (N = 18) | PsA (N = 20) | AS (N = 19) | |
|---|---|---|---|---|
| Age (years) | 43 (13) | 37 (15) | 41 (9) | 40 (12) |
| Female, n (%) | 7 (35) | 7 (39) | 7 (35) | 5 (26) |
| BMI (kg/m2) | – | 29.9 (7.9) | 27.7 (4.5) | 24.2 (3.4)* |
| Smoker, n (%) | – | 6 (40) | 7 (35) | 2 (11) |
| Disease duration (years) | ||||
| Pso | – | 12.4 (6.1–18.6) | 20.0 (7.2–31.4) | – |
| PsA | – | – | 0.7 (0.1–8.3) | – |
| AS | – | – | – | 5.6 (0.4–13.4) |
| NSAID use, n (%) | – | 1 (6)* | 11 (55) | 11 (58) |
| DMARD use, n (%) | – | 0 (0) | 2 (10) | 0 (0) |
| CRP (mg/l) | – | 2.8 (1–6) | 2.8 (2–4) | 3.2 (1–7) |
| ESR (mm/h) | – | 5 (2–8) | 5 (2–13) | 5 (3–14) |
| Pso indices | ||||
| PASI | – | 2.7 (2–7) | 3.0 (1–6) | – |
| Nail involvement, n (%) | – | 9 (56.3) | 13 (72) | – |
| Vulgaris type only, n (%) | – | 12 (67) | 14 (78) | – |
| SpA manifestations | ||||
| Swollen joint count, of 76 | – | – | 3 (1–9)* | 0 (0–0) |
| Tender joint count, of 78 | – | – | 3 (1–10)* | 0 (0–0) |
| Dactylitis ever, n (%) | – | – | 7 (35)* | 0 (0) |
| Enthesitis, n (%) | – | – | 9 (47)* | 3 (16) |
| Inflammatory back pain, n (%) | – | – | 3 (15)* | 19 (100) |
| BASDAI (range 0–10) | – | – | – | 4.2 (2–5) |
*
Significant (P-value <0.05). Presented data are from time of baseline visit, unless otherwise indicated. Categorical data are presented with frequencies (%) and continuous data are shown as mean (s.d.) (normally distributed variables) or median (interquartile range) (non-normally distributed variables). Pso: psoriasis; HC: healthy control; DMARD use: in past 3 months; NSAID use: daily on stable dose; PASI: Psoriasis Area and Severity Index (range 0–72).